TY - JOUR
T1 - Local secretion of IFN-γ induces an antitumor response
T2 - Comparison between T cells plus IL-2 and IFN-γ transfected tumor cells
AU - Sadanaga, Noriaki
AU - Nagoshi, Makoto
AU - Lederer, James A.
AU - Joo, Hong Gu
AU - Eberlein, Timothy J.
AU - Goedegebuure, Peter S.
PY - 1999
Y1 - 1999
N2 - Previously we described that the adoptive transfer of tumor-infiltrating lymphocytes (TIL) + interleukin-2 (IL-2) leads to eradication of established methyl-cholanthrene (MCA)-105 fibrosarcoma pulmonary metastases in a congenic murine model. The in vivo efficacy of TIL was associated with their ability to secrete interferon-γ (IFN-γ), and to a lesser extent granulocyte-macrophage colony-stimulating factor. The local secretion of these cytokines resulted in recruitment of naive host immune cells to the tumor and eventually in a successful host antitumor immune response. In the present study, to further evaluate the role of IFN-γ in the induction of a host antitumor immune response, we compared the treatment efficacy of adoptively transferred T cells and IFN-γ gene transfected tumor cells (MCA-105/IFN-γ) as delivery systems of IFN-γ. Treatment with TIL-IL-2 or irradiated MCA-105/IFN-γ induced a similar reduction in pulmonary metastases of MCA-105 tumor. In contrast, irradiated wild-type MCA-105 or TIL from IFN-γ gene knockout mice did not cause tumor eradication. MCA-105 tumor-bearing mice treated with MCA-205/IFN-γ showed a partial reduction in the number of pulmonary metastases. Histologically, lungs of successfully treated mice showed that initially activated macrophages expressing inducible nitric oxide synthase (iNOS) and dendritic cells infiltrated the tumor bed. Subsequently, CD4+ and CD8+ T cells infiltrated tumors. The therapeutic efficacy of IFN-γ transfected tumor cells was eliminated when either CD4+ T cells or CD8+ T cells were depleted. These results suggest that local secretion of IFN-γ induces a tumor-specific host antitumor immune response mediated through activated macrophages, dendritic cells, and tumor-specific T cells. This may be a common component of successful immunotherapy.
AB - Previously we described that the adoptive transfer of tumor-infiltrating lymphocytes (TIL) + interleukin-2 (IL-2) leads to eradication of established methyl-cholanthrene (MCA)-105 fibrosarcoma pulmonary metastases in a congenic murine model. The in vivo efficacy of TIL was associated with their ability to secrete interferon-γ (IFN-γ), and to a lesser extent granulocyte-macrophage colony-stimulating factor. The local secretion of these cytokines resulted in recruitment of naive host immune cells to the tumor and eventually in a successful host antitumor immune response. In the present study, to further evaluate the role of IFN-γ in the induction of a host antitumor immune response, we compared the treatment efficacy of adoptively transferred T cells and IFN-γ gene transfected tumor cells (MCA-105/IFN-γ) as delivery systems of IFN-γ. Treatment with TIL-IL-2 or irradiated MCA-105/IFN-γ induced a similar reduction in pulmonary metastases of MCA-105 tumor. In contrast, irradiated wild-type MCA-105 or TIL from IFN-γ gene knockout mice did not cause tumor eradication. MCA-105 tumor-bearing mice treated with MCA-205/IFN-γ showed a partial reduction in the number of pulmonary metastases. Histologically, lungs of successfully treated mice showed that initially activated macrophages expressing inducible nitric oxide synthase (iNOS) and dendritic cells infiltrated the tumor bed. Subsequently, CD4+ and CD8+ T cells infiltrated tumors. The therapeutic efficacy of IFN-γ transfected tumor cells was eliminated when either CD4+ T cells or CD8+ T cells were depleted. These results suggest that local secretion of IFN-γ induces a tumor-specific host antitumor immune response mediated through activated macrophages, dendritic cells, and tumor-specific T cells. This may be a common component of successful immunotherapy.
KW - Dendritic cells
KW - IFN-γ
KW - Immunotherapy
KW - MCA-105
KW - Macrophages
UR - http://www.scopus.com/inward/record.url?scp=0033023734&partnerID=8YFLogxK
U2 - 10.1097/00002371-199907000-00005
DO - 10.1097/00002371-199907000-00005
M3 - Article
C2 - 10404433
AN - SCOPUS:0033023734
SN - 1524-9557
VL - 22
SP - 315
EP - 323
JO - Journal of Immunotherapy
JF - Journal of Immunotherapy
IS - 4
ER -